Policy

All research work involving recombinant DNA; microbiological agents infectious to humans, animals or plants; select agents and biological toxins; materials from humans and non-human primates, transgenic animals, human gene clinical transfer; xenotransplant clinical studies and field studies involving animals must be reviewed and approved by <u>Boston University's</u> <u>Institutional Biosafety Committee (IBC)</u> and other applicable regulatory agencies before work can commence.

Responsibility

The Principal Investigator (PI) must complete, sign and submit the Biological Use Authorization to the IBC via the Research Information Management System (RIMS). The protocol will be reviewed and discussed at the next scheduled monthly committee meeting if it is received by the submission deadline. A PI who is submitting a new protocol for the first time must also provide a copy of the most current Bio-Sketch. The Bio-Sketch should follow the National Institute of Health (NIH) two-page format. The IBC may contact the PI for questions and comments prior to the scheduled monthly meeting. The PI must provide the information requested to avoid any delay in the review of the protocol. The PI should contact the IBC Office at 617-638-4263 or the Biosafety Office, Research Safety Division of the Office of Environmental Health and Safety (OEHS) at 617-638-842 for assistance in completing the protocol. The PI must be a faculty member. Applicants who are not faculty members may be listed as an Associate Investigator under the supervision of the PI. Sponsored Personnel are individuals that are sponsored by the PI for an individual project or grant. Post Docs and Fellows that apply for grants under their own names can not apply for an IBC protocol. They must have a faculty sponsor.

Renewals and Updates

Once the protocol is approved, it will be active for three years. The PI must resubmit a completed protocol for review by the IBC after three years before it expires. The IBC Office will send the PI a renewal notice to request an annual update before each annual anniversary date of the approval. The form must be promptly completed and submitted back to the IBC Office.

Amendments

Amendments must be submitted (electronic & hard copy) for changes within an approved project. All changes should be detailed in the amendment form which must be reviewed and approved by the IBC.

Compliance

The laboratory facilities must be inspected within the year prior to approval of the protocol. All laboratory personnel must also complete their annually-required Laboratory Safety Training prior to approval of the protocol. Pl's should call the Biosafety Office, Research Safety Division of OEHS for questions or assistance in this matter.


Click on the Save Changes button after completing this form.

Section I. Principal In	vestigator (MUST be BU Faculty member)	
PI Full Name*		
BU ID* BU Alias (Email)*		
Non BU Email]
Department*	· ·	1
School / College*		
Division / Section	<u> </u>	
Highest Degree Obtained	and Specialty	1
	Ph.D	
Institution	A Good Institution	
Office and Lab Information	ח:	
PI Office Address		
0/// 51		
Office Phone*	•	
Lab Phone*	?	
Fax]
Section II. Laboratory Name* Phone* Email*	Safety Coordinator Safety Coordinator Responsibilities	
	ontact for Emergencies 24 Hour Contact Responsibilities	
<i>Primar</i> y Name*	<i></i>	٦
Emergency Phone*		
Mobile and/or Pager		
Email*		
	lary (optional):	
Name		
Phone		
Mobile and/or Pager		
Email		
Section IV. Research	Safety Inspections	
Requires Research	Yes	
Safety Inspections?	No	
for Safety Inspections,		7
see this PI:	i est, Pi	

http://rims.bu.edu/servlet/forms?IFormDirId=1&action=2&pkg=3035&formDataId=6&sa... 8/25/2011

Safety S	cialist	
	Phone	
	Email	
Section V. Dep (This is the individ Purposes Only)	rtment Administrator al who will be contacted if the PI cannot be reached. Administrative Cor Name	ntact Information Is For Contact
Is the Department	Administrator a Boston University employee?	
	• Yes No	
/	ldress	
	Phone	
	Fax	
	Email	
Section VI. As	ociate Principal Investigator Name	
	BU ID	
	School	
Dep	tment	
	ection	
	Center	
,	Idress	
	Phone	
	Fax	
	Email	
Section VII. Sp	nsored Personnel	
	BU ID	
	School	
	Dept	
	ection	
	Center	
	Idress	
,	Phone	
	Fax	
	Email	

Asterisks (*) indicate required fie	elds	
PI BU ID PI BU Alias		
Project Litles	*New Annotations Test	
Specify if the research project is	a	
	* • New Project 3 Year Re-submittal	
	O Annual Renewal O Amendment	
What is the source of funding	*	
✓ Federal		
Non-Federal		
Other		
Is your grant administered throu	igh:	
	* Boston University - Medical Campus (ORA)	
	Boston University - Charles River Campus (OSP)	
	✓ Boston Medical Center (ORA)	
	Other (Specify)	
Othe	er test	
Anticipated Starting Date	* 08/17/2011	
PI CV Formatted in the standard	<u>d NIH 2 page Bio-Sketch format</u> :	
	Upload	
	tach IBC Application (PDF format):	
1.)	····	
2.)	Upload	
2.)	Upload	
Please upload any supporting d	ocumentation:	
1.)	Upload	



Director of Occupational Health for any research related medical needs at 617-353-6630 (Charles River Campus) or 617-638-8400 (Medical Campus). All staff who works

http://rims.bu.edu/servlet/forms?IFormDirId=1&action=2&pkg=3035&formDataId=29685... 8/25/2011

Page	2	of	2
------	---	----	---

with human materials including blood, tissue, cells and bodily fluids must be offered the Hepatitis B vaccine and antibody testing.
Has this individual completed and submitted their Initial Health Questionnaire?*
◯ Yes ◉ No
Will this individual be working with human materials?*
◯ Yes ◉ No
Has the individual submitted and completed an Authorization for Services for Hepatitis B Vaccine Series?*
◯Yes ◉No ◯N/A
Please explain why this has not been completed:
test
It is the PI's responsibility to ensure that anyone with potential exposure to blood borne pathogens in research studies or

It is the PI's responsibility to ensure that anyone with potential exposure to blood borne pathogens in research studies or in laborate is offered the Hepatitis B Vaccination Series and antibody testing. There are services administered by Research Occupational Heal Program in compliance with the Blood borne Pathogen Exposure Policy for Boston University/Boston University Medical Campus/B Medical Center. Anyone who declines the vaccine must still be offered the Hepatitis B Vaccine by Research Occupational Health P In addition to visible blood, Cerebral, Synovial, Pleural, Peritoneal, Pericardial and Amniotic fluids, unfixed human tissue, human de lines and human cell cultures are also considered potentially infectious.

Note: Hepatitis B virus has been demonstrated to survive in dried blood at room temperature on environmental surfaces for at lea week

Instructions: List all labora

List all laboratories and animal containment areas. To add additional locations, first click on Save Changes to save the current location, followed by the Add Additional Location b
PI* Test, PI ● PI BU ID* U55982740 ● PI Alias* bjgold ●
Research laboratory facility is: *
On-site ○ Off-site
On-site Location: BUMC Campus: BUMC Building: 580 HARRISON AVE Floor: 2 Room: 200B
Select a Building Select a Room OR Select from PI locations
General Information: Biological Safety Level BSL 1 BSL 2 BSL 2 w/ BSL 3 Practices BSL 3 BSL 4 Animal Biological Safety Level N/A ABSL 1 ABSL 2 ABSL 2 w/ ABSL 3 Practices
● ABSL 3 ○ ABSL 4
Is the research facility shared with another Principal Investigator?*
Yes ● No Most recent laboratory inspection date:*
Please state the finding/s not corrected:
test

The National Science Advisory Board for Biosecurity (NSABB) defined "dual use research of concern" as research that, be understanding, can be reasonably anticipated to provide knowledge, products, or technologies that could be directly misaply pose a threat to public health, agriculture, plants, animals, the environment, or materiel.

Please review the eight categories below and indicate if your research falls into any of the dual use research concu

PI Name^{*} Test, PI ● BU ID^{*} U55982740 ● BU Alias^{*} bjgold ●

Enhance the harmful consequences of a biological agent or toxin.

Disrupt immunity or effectiveness of an immunization without clinical and or agricultural justification

Confer to a biological agent or toxin, resistance to clinically and/or agriculturally useful prophylactic or therapeutic interventions against agent or toxin.

Confer to a biological agent or toxin, resistance to clinically and/or agriculturally useful prophylactic or therapeutic interventions against that agent or toxin, or facilitate their ability to evade detection methodologies.

Increase the stability, transmissibility, or the ability to disseminate a biological agent or toxin

Alter the host range or tropism of a biological agent or toxin.

Enhance the susceptibility of a host population.

Generate a novel pathogenic agent or toxin, or reconstitute an eradicated or extinct biological agent.

PI Name: * Test, PI PI BU ID: * U55982740 PI Alias: * bjgold ●

Provide a brief description of the project in 200 words or less

* test



Describe <u>laboratory procedures</u> and manipulations involved in the study. Provide sufficient detail for the reviewer to fully understand the potential health and environmental hazards associated with the project and any steps or procedures in place to limit the potential hazards

* test			

Describe the project in Layman's Terms. NIH requirement of 3 to 4 sentences about the goal of the experiment. This should be written in non-technical language (6th grade reading level) and should address foreseeable concerns for non-scientific lay community member. Avoid or fully explain any jargon or abbreviations.

This section will be available to the public as a synopsis of research. Be brief and concise and limit the number of words. Remember that many community members have reservations about the use of biohazards and rDNA in research.

* test

	Back fastening gowns
	Other (describe)
Other	
Indicate the personal protective e	quipment to be used in the animal containment to prevent potential exposure
	Laboratory coats
	Disposable gloves
	Goggles
	Safety glasses
	✓ Face shield
	Surgical mask
	Respirator (i.e. N95)
	Shoe cover
	Head cover
	Powered Air Purifying Respirator (PAPR)
	✓ Disposable scrubs
	Double gloves
	Back fastening gowns
	Other (describe)
Other	
Will Biological Safety Cabinets be	e used for this work?
•	Yes No
Will sharps be used in the studies	\$2
win sharps be used in the studiet	Yes No
	V Yes VNO
Describe how you will treat and d	ispose of the biological or biohazardous wastes: Key points to address
*	test
What disinfectant will be used:	
*	test
Is there a spill kit in the laboratory	
	U Tes U No
How and where are biohazardous	s materials stored? Key points to address
*	test
Describe how biohazardous mate Key points to address	rials are transported (indicate nature of primary and secondary containers)?
*	test

PI Name^{*} Test, PI PI BU ID^{*} U55982740 PI BU Alias^{*} bjgold ●

Indicate all laboratory manipulations involved in the research protocol that have the potential to produce aerosols or droplets

	Homogenizing, tissue grinding
	Vortexing
	Vigorous mixing, blending
	🗹 Freeze drying, lyophilizing
	Sonicator, ultrasonic cleaners
	Animal handling, cage changing
	Pipetting infectious liquid
	Centrifugation, ultra centrifugation
	Opening containers under pressure
	Culture stirrers, shakers
	Plating, colony counting
	Animal inoculations
	Animal aerobiology exposure
	Other (Specify)
Other	

Indicate the engineering controls in place to prevent potential exposure from procedures described

Work that produce/ or potentially produce aerosols are done in the Biological Safety Cabinet or other containment equipment

- ✓ Use centrifuge with sealed rotor or sealed cups
- V HEPA and hydrophobic filter protection on the vacuum line
- Gasket blenders/ homogenizers
- Others (describe)

Other

Indicate the personal protective equipment to be used in the *laboratory* to prevent potential exposure

Laboratory coats
✓ Disposable gloves
Goggles
Safety glasses
Face shield
Surgical mask
Respirator (i.e. N95)
Shoe cover
Head cover
Powered Air Purifying Respirator (PAPR)
✓ Disposable scrubs
✓ Double Gloves

PI Name* Test, PI ● PI BU ID* U55982740 ● PI BU Alias* bjgold ●

If your research involves the following materials or activities (check all that apply)	Example/Description	Then
Hazardous Biological Agent including Human Cells and Cell Line	Viruses, Bacteria, Fungi, Parasites, Rickettsia, Prion, Human Primary or Cell Lines, Non Human Primate Primary or Cell Lines	Complete a <i>Hazardous</i> <i>Biological Agent</i> form for each Agent
Other Potentially Infectious Materials	Other Human Material: Blood, Plasma, Serum, Unfixed Tissue, Organs, Unfixed Cells, Other; Other Non-Human Primate Material: Blood, Plasma, Serum, Unfixed Tissue, Organs, Unfixed Cells, Other; Sheep Material: Unfixed Tissue, Other	Complete a <i>Potentially</i> <i>Infectious Material</i> form for each Material
Human Embryonic Stem Cell	Human Embryonic Stem Cell	Complete a <i>Human</i> <i>Embryonic Stem Cell</i> form
Select Biological Toxins	Abrin, Botulinum neurotoxins, Conotoxin, Clostridium perfringens epsilon toxin, Diacetoxyscirpenol (DAS), Ricin, Staphylococcal enterotoxins, Saxitoxin, Shiga-like ribosome inactivating proteins, Shigatoxin, Tetrodotoxin, T-2 toxin	Complete a <i>Select</i> <i>Biological Toxins</i> form
Field Study with Animals or Insect Vector	Environmental or field studies with animals	Complete a Field Study with Animals or Insect Vectors form
✓ High Hazard Chemical	Use of a high hazard chemical	Complete a <i>High Hazard</i> <i>Chemical</i> form for each Chemical
Radiation and X- Ray	Use of Radioactively-labeled compounds; Inject animals with radioactive-labeled compounds; X-ray or other imaging of speciments; Use of the irradiator	Complete a Radiation and X-ray form
Recombinant DNA	In the context of this application, recombinant DNA molecules are defined as molecules that are constructed outside living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell or those resulting from such replication. Synthetic DNA segments which are likely to yield a potentially harmful polynucleotide or polypeptide are considered as equivalent to their natural DNA counterpart. If the synthetic DNA segment is not expressed in vivo or is biologically active, polynucleotide or polypeptide product, it is exempt from the NIH Guidelines (NIH Guidelines for Research Work Involving Recombinant DNA Molecules).	Complete a <i>Recombinant DNA</i> form and Public Health Commission Form
Synthetically derived nucleic acid	The work involves the creation of synthetically derived nucleic acid molecules	Complete relevant section on the <i>Recombinant DNA</i> form

molecules		
Live Animal Use	For work involving the use of biohazardous materials or recombinant DNA in live animals	Complete the relevant sections of the Hazardous Biological Agent form or Recombinant DNA form, respectively

Highest BSL necessary for this project:

◯ BSL-1 ● BSL-2 ◯ BSL-2 with special practices of BSL-3

OBSL-3 OBSL-4

Is this a hospital-based project?

🔵 Yes 💽 No

Instructions:

List all hazardous biological agents. To add additional agents, first click on Save Changes to save the current agent, followed by the Add Agent button.

	_
PI Name:	ēst, PI ♥ J55982740 ♥
	okup results by agent class select one before hitting lookup
-	Absidia corymbifera, AP
-	·
Strain:	
Agent Class: *	-
Obtained From: (i.e. ATCC, BU researcher, etc.)*	est
BSL: *	BSL-2
-	Lookup
Does the Genus and species of biologi	c agent that you are proposing to conduct experiments with cause human disease?*
	◯Yes ◯No
Is the particular strain(s) that you propo	ose to work with attenuated?*
	◯Yes ◯No
For pathogenic prokaryotes, is an antib	iotic resistance marker being introduced?
	◯Yes ◯No ◯N/A
Is the microbiological agent classified a	Select Agent by CDC/USDA? List of all Select Agents*
	◯Yes
Is the agent an attenuated strain of a B	SL3 or BSL4 microbiological agent?*
	Ves No
The IBC requires that the attenuated st	rain is verified prior to being used in the laboratory. Please provide the name and

contact number of the laboratory that will verify your sample. You must also submit a copy of the verification result.

Lab Name

Lab Contact # Verification Results Upload

Will live animals be used with this agent? *

🔵 Yes 💽 No

Are all equipment used for biohazardous materials work affixed with biohazard warning labels?*

🔵 Yes 💿 No

Do you have IRB (Institutional Review Board) approval related to this agent?*

○Yes

○Yes
○Pending

Instructions:

List all potentially Infectious Materials.

To add additional potentially infectious material, first click on Save Changes to save the current infectious material, followed by the Add Potentially Infectious Material button.

PI Name* 1 PI BU ID* U PI Alias*b	J55982740 🛨
Class*	Other Human Material
	Non-Human Primate Material
	Sheep Material
	Other
Type of Material*	Blood
	✓ Plasma
	Serum
	Unfixed Tissue
	✓ Organs
	Cells
	Other
Other Type 1	lest
Source of Material* t	est

Do you have IRB (Institutional Review Board) approval related to this project?*

○Yes
No ○Pending

Name of Cell Line(s)* Test, PI • PI BU ID* U55982740 • PI Alias* bjgold •

Is the HESC an approved cell line listed in the NIH Human Embryonic Stem Cell Registry?

🔵 Yes 🧿 No

Name of Cell Line(s)* test

PI Name^{*} Test, PI ● PI BU ID^{*} U55982740 ● PI Alias^{*} bjgold ●

A laboratory that possess a Select Agent Biological Toxin that is less than the maximum excluded amount set by CDC and USDA is exempt from the requirement of the Select Agent regulation. The list of Biological Toxin maximum excluded amount is available at: <u>http://www.cdc.gov/od/sap/sap/toxinamt.htm</u>

If the study involves the use of biological toxins listed by CDC/USDA as Select Agents, provide the total amount to be possessed in the lab for the Biological Toxin/s you will use or possess

Abrin:	test
Botulinum neurotoxins:	
Clostridium perfringens epsilon toxin:	
Conotoxin:	
Diacetoxyscirpenol (DAS):	test
Ricin:	
Staphylococcal enterotoxins:	
Saxitoxin:	test
Shiga-like ribosome inactivating proteins:	
Shigatoxin:	
Tetrodotoxin:	
T-2 toxin:	

Asterisks (*) indicate required fields		
PI Name* Test, PI ▪ PI BU ID* U55982740 ▪ PI Alias* bjgold ▪		
Check all that apply		
Capture, study ar	nd release animals back to the environment or field.	
Capture and bring	g back live animals to BU.	
Capture and bring	g back animal carcass or tissue to BU	
Please provide the IACUC approval I	number for the study, Species, and ABSL.	
Do animals need to be quarantined p	prior to your use in the study?*	
🔵 Yes 💿 No		
If YES, provide the animal containme	ent:	
Building	Room	Loc
Is there vaccination recommendation	n for the activity and type of animals involved in this project?*	
🔵 Yes 💿 No		
For Rabies, provide annual titer chec	sk	
test		
Will you bring a first aid kit with you in	n the field*	
◯ Yes ● No		
Why not? test		

.

Asterisks (*) indicate required fields

PI Name* Test, PI 🛨 PI BU ID* U55982740 🛨 PI BU Alias* bjgold 🛨 Instructions: List all high hazard chemicals. To add additional chemicals, first click on Save Changes to save the current chemical, followed by the Add High Hazard Chemical button.

HLORO-4-NITROBENZENE, 1-	Lookup
00-00-5	
st	
st	
st	
	00-00-5 st st

PI Name* Test, PI ● PI BU ID* U55982740 ● PI Alias* bjgold ●

Will the study involve the use of Radioactively-labeled compounds?	
*	◯Yes
Will you inject animals	with Radioactively-labeled compounds?
*	◯Yes ● No
Will you perform X-ray	or other imaging of specimens?
*	◯Yes ●No
Will you use the Irradia	ator?
*	◯Yes ●No

PI Name^{*} Test, PI ● PI BU ID^{*} U55982740 ● PI Alias^{*} bjgold ●

In the context of this application, recombinant DNA molecules are defined as molecules that are constructed outside living DNA molecules that can replicate in a living cell or those resulting from such replication. Synthetic DNA segments which ar polypeptide are considered as equivalent to their natural DNA counterpart. If the synthetic DNA segment is not expressed i polypeptide product, it is exempt from the NIH Guidelines (NIH Guidelines for Research Work Involving Recombinant DNA

*If using rDNA, please complete the Public Health Commission Environmental Health Office Registration Form for Boston Public Health Commission and is a stand-alone document.

Will rDNA gene be expressed?	
*	◯Yes ●No
Will the experiments involve rDNA molecules ca	pable of expressing a pathogenic polynucleotide or polypeptide?
*	◯Yes ●No
Will the experiments involve the expression of rD	NA encoding toxins with LD50 <100 ng/kg body weight?
*	◯Yes ●No
Will rDNA construct be provided to another PI fo	r their studies?
	◯Yes ●No
Will the experiment involve the deliberate transfe	er of a drug resistance trait to microorganisms that are not known to acquire
*	◯Yes ●No
Does the work involve the use or creation of dou	ble stranded synthetic nucleic acid that is 200 bps in length or greater?
*	◯Yes ●No
Is the viral vector defective?	
*	◯Yes ●No ◯N/A
Is the viral vector replication competent?	
*	◯Yes ◉ No ◯N/A
Will transgenic or knockout animals be used in the	ne experiments?
*	◯Yes ●No
Will the experiment involve more than 10 liters o	f culture (large scale)?
*	◯Yes ● No
Specify the relevant section of the NIH Guideline	e for Research Work Involving Recombinant DNA
*	test

Public Health Commission Environmental Health Office

Registration Form For rDNA Projects

Principal Investigator: Test, PI

Project Title:		
test		
Anticipated Starting Date:		
08/17/2011		
Brief Description of Project:		
test		
Institution Name:		
Boston University - Charles Ri	iver Campus (OSP), Boston Medical Center	(ORA)

Other: test

Lab	Facility	Address	(es):
test			

Building(s): 580 HARRISON AVE

Room(s): 200B

Are Large Scale V	olumes Used (>= 10 liters)?
No	
Is an rDNA gene p	product efficiently expressed?

- OYes
- No

Containment levels:
Highest BSL:
BSL-2
NIH Guideline:
test 🛨

Host-Vector Donor System:	
test	

Lab Personnel to contact in emergency situations requiring immediate remedial action: 24Hour, Name Emergency Phone: 353-7233

PI Name Test, PI PI BU ID U55982740 PI BU Alias bjgold

Is the following IBC application complete in its entirety?

Yes No

As the Principal Investigator of this project, I certify that the information contained in this application is accurate and complete. I agree to comply with any requirements posed by the Institutional Biosafety Committee (IBC) and pertinent regulatory requirements.

I agree to abide by the following requirements (Check all):

I will not initiate experimentation until this research project has been approve by the IBC.

V I will follow appropriate Biosafety Level laboratory techniques required for this project.

I will comply with all shipping requirements for materials, as appropriate.

I will provide to the laboratory staff copies of the approved protocols which describes the potential biohazards and the precautions that must be taken.

▶ I will train the staff in good microbiological practices and techniques required to ensure safety for this project, and in the procedures for dealing with accidents and waste management.

I will ensure that all laboratory workers are registered with the IBC.

I will supervise the staff and correct work errors and conditions that could result in breaches of the Biosafety Manual, Exposure Control Plan, Chemical Hygiene Plan and other plans as appropriate.

I will submit an amendment for any changes/ additional work to be performed that go beyond the range of the current protocol (before work begins).

I will obtain required additional approvals if my work involves animals from institutional Animal Care & Use Committee (IACUC) or for the use of primary human tissues or cells from the Institutional Review Board (IRB)

■ I will contact Research Occupational Health Program (ROHP) 24/7 at (617) 414-7647 immediately after a potential exposure or accident in my lab.